Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aethlon Medical, Inc. AEMD

Healthcare  —  Medical Devices
6.28 (0.49) (7.24%) as of 25 Sep
Market cap
$10.4M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aethlon Medical, Inc. (AEMD) Business Profile

Updated before January 2025

Company Overview

Aethlon Medical, Inc. (NASDAQ: AEMD) is a pioneering medical technology company focused on addressing unmet needs in health care through innovative therapeutic solutions. Founded in 1998 and headquartered in San Diego, California, Aethlon specializes in developing medical devices and technologies that target life-threatening diseases, including cancer, infectious diseases, and other critical health conditions. The company was co-founded by James A. Joyce, who served as its CEO for many years and played a pivotal role in shaping its vision. Currently, the leadership team includes Charles J. Fisher Jr., M.D., as the CEO, who brings extensive experience in clinical research and biotechnology. Aethlon’s mission is to improve global health outcomes by leveraging advanced medical technologies to address complex medical challenges.

Core Business Segments

Aethlon Medical operates primarily in the medical device and biotechnology sectors. Its core business revolves around the development and commercialization of therapeutic devices and technologies. The company’s flagship product is the Hemopurifier, a first-in-class device designed to selectively remove harmful substances from the bloodstream. Below are the major product categories:

Hemopurifier

The Hemopurifier is Aethlon’s most notable product and is designed to combat life-threatening diseases by filtering viruses, exosomes, and other harmful particles from the blood. It has shown promise in treating infectious diseases such as HIV, hepatitis C, and even emerging threats like Ebola and COVID-19. The device is also being explored for its potential in oncology, particularly in removing tumor-derived exosomes that suppress the immune system.

Research and Development Services

Aethlon is heavily invested in R&D to expand the applications of its Hemopurifier and develop new therapeutic solutions. The company collaborates with government agencies, academic institutions, and private organizations to advance its technologies. These partnerships have enabled Aethlon to secure grants and funding for its research initiatives.

Clinical Trials and Regulatory Approvals

Aethlon is actively involved in conducting clinical trials to validate the safety and efficacy of its products. The company works closely with regulatory bodies such as the FDA to obtain necessary approvals, which are critical for commercializing its technologies.

Business Model

Aethlon Medical’s business model is centered on innovation, collaboration, and commercialization. The company generates revenue through the following channels:

  1. Product Sales: Once approved, the Hemopurifier and other devices are sold to hospitals, clinics, and healthcare providers.
  2. Research Grants: Aethlon secures funding from government agencies and private organizations to support its R&D efforts.
  3. Collaborations and Partnerships: The company partners with academic institutions, biotech firms, and government entities to co-develop technologies and share resources.
  4. Licensing and Royalties: Aethlon may license its technologies to other companies, generating additional revenue streams.

Strategic Direction

Aethlon Medical is focused on expanding the applications of its Hemopurifier and exploring new therapeutic areas. Key strategic initiatives include:

  • Oncology Applications: The company is investigating the use of the Hemopurifier in cancer treatment, particularly in removing tumor-derived exosomes.
  • Global Expansion: Aethlon aims to enter new markets by obtaining regulatory approvals in regions such as Europe and Asia.
  • Sustainability Goals: The company is committed to developing cost-effective and environmentally sustainable medical technologies.
  • Pipeline Development: Aethlon is exploring new product categories and therapeutic areas to diversify its portfolio and reduce dependence on a single product.

Competitive Landscape

Aethlon Medical operates in a highly competitive and rapidly evolving industry. Key competitors include:

  • Exosome Diagnostics: Specializes in exosome-based diagnostics and therapeutics.
  • CytoSorbents Corporation: Develops blood purification technologies for critical care.
  • Fresenius Medical Care: A global leader in dialysis and extracorporeal therapies.
  • Thermo Fisher Scientific: Offers a wide range of medical devices and diagnostic tools.

Despite the competition, Aethlon differentiates itself through its innovative Hemopurifier technology and focus on addressing unmet medical needs.

Risk Factors

Aethlon Medical faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: Delays or failures in obtaining FDA and other regulatory approvals could hinder product commercialization.
  • Market Dependence: The company’s reliance on the Hemopurifier as its primary product poses a significant risk.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers could lead to production delays.
  • Financial Constraints: As a small-cap company, Aethlon may face challenges in securing sufficient funding for its operations and R&D efforts.
  • Competitive Pressure: Larger, well-established competitors with greater resources could limit Aethlon’s market share.

Recent Developments

  • COVID-19 Applications: Aethlon has explored the use of its Hemopurifier in treating COVID-19 patients, demonstrating its versatility in addressing emerging health threats.
  • FDA Breakthrough Device Designation: The Hemopurifier has received FDA Breakthrough Device Designation, which facilitates expedited development and review processes.
  • Partnerships and Grants: The company has secured new research grants and partnerships to advance its technologies.
  • Clinical Trials: Aethlon is conducting clinical trials to expand the indications for its Hemopurifier, including applications in oncology and infectious diseases.

Investment Considerations

Strengths

  • Innovative Technology: The Hemopurifier is a unique, first-in-class device with broad applications.
  • Strong Leadership: Experienced management team with expertise in biotechnology and clinical research.
  • Growth Potential: Expanding applications and markets for the Hemopurifier offer significant growth opportunities.
  • Regulatory Support: FDA Breakthrough Device Designation enhances the company’s credibility and accelerates product development.

Risks

  • Financial Uncertainty: Limited revenue streams and high R&D costs could strain the company’s finances.
  • Regulatory Hurdles: Delays in obtaining approvals could impact commercialization timelines.
  • Market Competition: Larger competitors with established products pose a threat to market penetration.

Conclusion

Aethlon Medical, Inc. is a trailblazer in the medical technology industry, offering innovative solutions to address critical health challenges. With its flagship Hemopurifier device, the company is well-positioned to make a significant impact in oncology, infectious diseases, and other therapeutic areas. While it faces challenges such as regulatory hurdles and financial constraints, Aethlon’s strong leadership, innovative technology, and strategic initiatives provide a solid foundation for future growth. Investors should weigh the company’s strengths and risks carefully, but its potential for long-term success in a rapidly evolving industry is undeniable.